Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …

Idiopathic pulmonary fibrosis (IPF) remains a disease with poor survival. The pathogenesis
is complex and encompasses multiple molecular pathways. The first-generation antifibrotics …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Recent studies have
identified the key role of crosstalk between dysregulated epithelial cells, mesenchymal …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs
primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality …

Idiopathic pulmonary fibrosis (IPF) is a long-lasting, continuously advancing, and irrevocable
interstitial lung disorder with an obscure origin and inadequately comprehended …

Idiopathic pulmonary fibrosis is a nonmalignant disease, yet it carries a prognosis akin to, or
even worse than, many cancers. Until recently, lung transplantation has been the only …

The two novel drugs approved for IPF, pirfenidone and nintedanib, open a new scenario in
which treated patients with fibrosis will live longer, and possibly have a lower incidence of …